Is June set to be the month of the ASX healthcare rebound?
The article says the S&P/ASX 200 Health Care Index is about 33% lower year-to-date, making healthcare the worst ASX sector in 2026, citing earnings downgrades, higher costs, weaker overseas earnings and slower growth concerns. It highlights Pro Medicus (up 9% to $144.46; broker target $187.27), ResMed (52-week low $26.27; Morgans target $41.72) and Sonic Healthcare (target $23.40).
Selloff-to-value setup: sharp recent decline plus a quantified rebound target may attract dip-buying.
ResMed shares fell more than 7% to a new 52-week low, with a broker expecting a rebound and giving a 12-month price target.
Potential mean-reversion bounce, but magnitude uncertain given the stock is at a 52-week low.
Background
ASX healthcare has underperformed in 2026 (~33% lower for the Health Care Index), attributed to earnings downgrades, rising costs, weaker overseas earnings, and growth-slowing concerns amid higher rates and rotation to resources.
Why it matters
The article frames June as a potential inflection point and highlights three large ASX healthcare names with either a near-term catalyst (PME contract win) or sharp drawdowns plus analyst rebound targets (RMD, SHL).
Market relevance
Provides catalyst/price-action context and quantified analyst targets that can inform tactical positioning in ASX healthcare names.
Market effects
Highlights broad ASX healthcare pressure from earnings downgrades, cost pressures, and rotation out of growth; could influence sector ETF/peer sentiment.
Potentially supports a June “healthcare rebound” narrative in Australian equities, affecting flows into the ASX 200 Health Care Index constituents.
Read-across to global healthcare/sleep-imaging themes is limited; the catalysts cited are company-specific and ASX-focused.
Alternative perspectives
Broker price targets may reflect optimism that the sector’s earnings/cost headwinds persist; rebounds could fade if downgrades continue.
No new earnings/guidance details are provided; for SHL especially, the article lacks a fresh catalyst, so technical/valuation mean reversion may dominate rather than fundamentals.
Key entities
- companyPro Medicus Ltd
Medical imaging technology firm; shares jumped >9% on a key contract win and are still down 35% YTD.
- companyResMed Inc
Sleep technology leader; shares dropped >7% to a new 52-week low and are down 26% YTD.
- companySonic Healthcare Ltd
Global healthcare provider; shares down >14% YTD with an average one-year analyst target cited.
